Glenmark Pharma teams up with Canadian firm produce anti-COVID nasal spray
In line with the recommendations of the CDSCO's Subject Expert Committee (SEC), phase 3 clinical trials of the nasal spray are currently underway02-08-2021
02-08-2021
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark inks agreement with Canadian biotech SaNOtize to commercialize Nitric Oxide Nasal Spray for COVID-19 treatment in India and other Asian markets02-08-2021
Glenmark Life raises Rs454 cr via 19 anchor investors
The company in consultation with merchant bankers finalised allocation of 6.31 million shares to anchor investors, at a price of Rs720 a share26-07-2021
Glenmark Life Sciences to invest Rs 600 cr to double capacity in four years
Glenmark Life Sciences is the arm of drug major Glenmark Pharmaceuticals.22-07-2021
Glenmark's 12-year wait to unlock value ends with Life Sciences IPO
Glenmark is set to receive at least 800 crore from fund raising by its subsidiary Glenmark Life Sciences22-07-2021
Glenmark Lifesciences to double manufacturing capacity in five years
With formulation makers aiming at de-risk procurement by creating one more source for raw material other than China, the demand for APIs is rising, says company21-07-2021
Glenmark Pharmaceuticals Ltd - 532296 - Filing And Approval Of The Red Herring Prospectus ('RHP') Dated July 19, 2021 Of Our Wholly Owned Subsidiary 'Glenmark Life Sciences Limited' In Connection With Its Proposed Initial Public Offering Of Equity Shares ('Offer' Or 'IPO')
Further to our intimation dated April 16, 2021 regarding submission of the draft red herring prospectus dated April 16, 2021 ('DRHP') with the Securities and Exchange Board of India, by our wholly owned subsidiary, Glenmark Life Sciences Limited, please be informed that on July 19, 2021, Glenmark Life Sciences Limited had filed the RHP with the Registrar of Companies, Pune at Maharashtra ('ROC') in connection with the Offer. The RHP has been taken on record by the ROC on July 20, 2021.20-07-2021
GLENMARK PHARMACEUTICALS LTD. - 532296 - Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- Harish KuberDesignation :- Company Secretary and Compliance Officer14-07-2021
Glenmark Pharma Q1 PAT seen up 23.3% YoY to Rs 313.1 cr: KRChoksey
Net Sales are expected to increase by 23.1 percent Y-o-Y (up 1 percent Q-o-Q) to Rs 2,887 crore, according to KRChoksey.13-07-2021
GLENMARK PHARMACEUTICALS LTD. - 532296 - Shareholding for the Period Ended June 30, 2021
Glenmark Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2021. For more details, kindly Click here12-07-2021